Unknown

Dataset Information

0

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.


ABSTRACT:

SUBMITTER: Malissen N 

PROVIDER: S-EPMC8352671 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.

Malissen Nausicaa N   Ninove Laetitia L   de Lamballerie Xavier X   André Nicolas N   Gaudy-Marqueste Caroline C  

European journal of cancer (Oxford, England : 1990) 20210810


Similar Datasets

| S-EPMC9472569 | biostudies-literature
| S-EPMC8174030 | biostudies-literature
| S-EPMC10581992 | biostudies-literature
| S-EPMC9745767 | biostudies-literature
| S-EPMC9485492 | biostudies-literature
| S-EPMC8700280 | biostudies-literature
| S-EPMC9530261 | biostudies-literature
| S-EPMC3417327 | biostudies-literature
| S-EPMC8382485 | biostudies-literature